| Abnormality Detection |
Ryan Chamberlain |
Invenshure LLC |
NLST |
Oct 8, 2015 |
NLST-168 |
| The Autonomous Collection and Databasing of Cancer and Structural Specific Features Present in CT Based Cancer Images through mathematical imaging based Systems |
Jaffar Ali Shahul Hameed |
Florida Gulf Coast University |
NLST |
Oct 7, 2015 |
NLST-166 |
| Virtual biopsy of pulmonary nodules |
Francesco Ciompi |
Radboud University Medical Center |
NLST |
Sep 30, 2015 |
NLST-164 |
| Circulating inflammatory markers and urinary metabolites in combination with low dose computed tomography screening (LDCT). |
Curtis Harris |
NCI |
NLST |
Sep 25, 2015 |
NLST-165 |
| Regional CT Parenchymal Abnormalities as Radiographic Biomarkers for Lung Cancer |
C. Matthew Kinsey |
University of Vermont College of Medicine |
NLST |
Sep 24, 2015 |
NLST-163 |
| NLST screen detected cardiovascular disease - impact on mortality and lung cancer screening |
Martin Tammemagi |
Brock University |
NLST |
Sep 21, 2015 |
NLST-162 |
| The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: The Operations Behind a Herculean Task |
Pam Marcus |
NCI |
PLCO |
Sep 16, 2015 |
PLCO-155 |
| The importance of publishing on clinical trial operations |
Pam Marcus |
NCI |
PLCO |
Sep 16, 2015 |
PLCO-156 |
| The PLCO Cancer Screening Trial: Background, Goals, Organization, Operations, Results |
Pam Marcus |
NCI |
PLCO |
Sep 16, 2015 |
PLCO-157 |
| Building Successful Relationships in the PLCO Cancer Screening Trial |
Pam Marcus |
NCI |
PLCO |
Sep 16, 2015 |
PLCO-158 |
| Managing Multi-Center Recruitment in the PLCO Cancer Screening Trial |
Pam Marcus |
NCI |
PLCO |
Sep 16, 2015 |
PLCO-159 |
| Validation of Self-Report of Chest X-Ray Exam at a Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Center |
Pam Marcus |
NCI |
PLCO |
Sep 16, 2015 |
PLCO-160 |
| Lessons in Medical Record Abstraction from the Prostate, Lung, Colorectal, and Ovarian (PLCO) National Screening Trial |
Pam Marcus |
NCI |
PLCO |
Sep 16, 2015 |
PLCO-161 |
| Changes in and Impact of the Death Review Process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial |
Pam Marcus |
NCI |
PLCO |
Sep 16, 2015 |
PLCO-162 |
| The PLCO Biorepository: Creating, Maintaining, and Administering a Unique Biospecimen Resource |
Pam Marcus |
NCI |
PLCO |
Sep 16, 2015 |
PLCO-163 |
| Comprehensive Quality Management (CQM) in the PLCO Trial |
Pam Marcus |
NCI |
PLCO |
Sep 16, 2015 |
PLCO-164 |
| Data Processing and Analytic Support in the PLCO Cancer Screening Trial |
Pam Marcus |
NCI |
PLCO |
Sep 16, 2015 |
PLCO-165 |
| PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies |
Black Amanda |
NCI |
PLCO |
Sep 16, 2015 |
PLCO-166 |
| Estimating the cost effectiveness of lung screening in the Australian setting |
Marianne Weber |
Cancer Council NSW |
NLST |
Sep 15, 2015 |
NLST-161 |
| Time-specific measures of benefits due to screening |
Olli Saarela |
University of Toronto |
NLST |
Sep 10, 2015 |
NLST-158 |
